Regulus Therapeutics (NASDAQ:RGLS) Issues Earnings Results

Regulus Therapeutics (NASDAQ:RGLS) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20), Zacks reports. During the same period in the previous year, the firm earned ($0.40) earnings per share.

Regulus Therapeutics Stock Performance

NASDAQ:RGLS opened at $1.37 on Friday. The stock has a 50-day simple moving average of $1.27 and a 200-day simple moving average of $1.45. The stock has a market cap of $90.75 million, a P/E ratio of -1.28 and a beta of 1.42. Regulus Therapeutics has a 1 year low of $0.83 and a 1 year high of $3.00.

Insider Transactions at Regulus Therapeutics

In related news, CFO Crispina Calsada sold 38,716 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the sale, the chief financial officer now directly owns 50,566 shares of the company’s stock, valued at $63,713.16. This represents a 43.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Christopher Ray Aker sold 38,547 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now directly owns 54,634 shares of the company’s stock, valued at approximately $68,838.84. This trade represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 223,998 shares of company stock valued at $282,237. 4.35% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, March 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $28.00 price target on shares of Regulus Therapeutics in a research note on Monday, March 17th.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.